t-dxd
Entity, reached from Hormuz.
- Evidence
- 16 documents · 3 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 16 May 2026, last seen 6 Oct 2026
- Measured
- 19% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- The ASCO Post · 2026-09-22 · Metastatic HER2-Mutant NSCLC First-Line T-DXd (opens the source in a new tab)
- The ASCO Post · 2026-09-10 · Additional Safety Analysis of DESTINY-Breast05: What Did It Show? (opens the source in a new tab)
- FDA Drug News · 2026-05-16 · [APPROVAL] FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer (opens the source in a new tab)
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with her2 (16 documents)seen together
- co-mentioned with her2-directed (15 documents)seen together
- co-mentioned with egfr (13 documents)seen together
- co-mentioned with lung cancer (12 documents)seen together
- co-mentioned with egfr-mutated (11 documents)seen together
- co-mentioned with her2-mutant (11 documents)seen together
- co-mentioned with cancer center (9 documents)seen together
- co-mentioned with dana-farber cancer institute (9 documents)seen together
- co-mentioned with ros1-positive (9 documents)seen together
- co-mentioned with wclc (9 documents)seen together